196 related articles for article (PubMed ID: 17724350)
41. [Raloxifene for the treatment of osteoporosis].
Okazaki R
Nihon Naika Gakkai Zasshi; 2005 Apr; 94(4):702-7. PubMed ID: 15864998
[No Abstract] [Full Text] [Related]
42. Tamoxifen versus raloxifene in the prevention of breast cancer.
Wickerham DL
Eur J Cancer; 2002 Nov; 38 Suppl 6():S20-1. PubMed ID: 12409060
[No Abstract] [Full Text] [Related]
43. [Raloxifene, selective estrogen receptor modulator (SERM). Introduction and conclusion].
Audran M
Joint Bone Spine; 2000; 67 Suppl 1():3s-6s, 23s-25s. PubMed ID: 10769108
[No Abstract] [Full Text] [Related]
44. Report examines strategies for reducing breast cancer risk.
Miller JL
Am J Health Syst Pharm; 1999 Jul; 56(13):1298. PubMed ID: 10683123
[No Abstract] [Full Text] [Related]
45. Preventive therapy for breast cancer: a consensus statement.
Cuzick J; DeCensi A; Arun B; Brown PH; Castiglione M; Dunn B; Forbes JF; Glaus A; Howell A; von Minckwitz G; Vogel V; Zwierzina H
Lancet Oncol; 2011 May; 12(5):496-503. PubMed ID: 21441069
[TBL] [Abstract][Full Text] [Related]
46. Osteoporosis drug effective in preventing breast cancer.
Mayo Clin Health Lett; 2007 Apr; 25(4):4. PubMed ID: 17494193
[No Abstract] [Full Text] [Related]
47. Anti-Estrogen Withdrawal Effect With Raloxifene? A Case Report.
Lemmo W
Integr Cancer Ther; 2016 Sep; 15(3):245-9. PubMed ID: 27411856
[TBL] [Abstract][Full Text] [Related]
48. Primary prevention of breast cancer: new approaches.
Cummings SR
Maturitas; 2007 May; 57(1):39-41. PubMed ID: 17391879
[TBL] [Abstract][Full Text] [Related]
49. Selective estrogen receptor modulators.
Kearney CE; Purdie DW
Climacteric; 1998 Jun; 1(2):143-7. PubMed ID: 11907917
[No Abstract] [Full Text] [Related]
50. The rise of raloxifene and the fall of invasive breast cancer.
Jordan VC
J Natl Cancer Inst; 2008 Jun; 100(12):831-3. PubMed ID: 18544739
[No Abstract] [Full Text] [Related]
51. An update on breast cancer prevention trials.
Wickerham DL; Fourchotte V
Int J Gynecol Cancer; 2006; 16 Suppl 2():498-501. PubMed ID: 17010056
[TBL] [Abstract][Full Text] [Related]
52. Exemestane for primary prevention of breast cancer in postmenopausal women.
Zhang Y; Simondsen K; Kolesar JM
Am J Health Syst Pharm; 2012 Aug; 69(16):1384-8. PubMed ID: 22855103
[TBL] [Abstract][Full Text] [Related]
53. Measurement of serum estradiol.
McKiernan F; Wiley C
JAMA; 2002 Mar; 287(12):1528. PubMed ID: 11911752
[No Abstract] [Full Text] [Related]
54. [Evidence of raloxifene on postmenopausal osteoporosis].
Okano H
Nihon Rinsho; 2007 Nov; 65 Suppl 9():374-80. PubMed ID: 18161135
[No Abstract] [Full Text] [Related]
55. [Raloxifene - an unexploited possibility of prevention and treatment of postmenopausal osteoporosis].
Štěpán J; Rosa J; Pavelka K
Vnitr Lek; 2016; 62(10):781-788. PubMed ID: 27900864
[TBL] [Abstract][Full Text] [Related]
56. The role of the primary care physician in the prevention, diagnosis and treatment of breast cancer: contemporary knowledge and controversies.
Braverman AS
South Med J; 2010 Apr; 103(4):287-8. PubMed ID: 20224482
[No Abstract] [Full Text] [Related]
57. In pursuit of the prevention of breast cancer.
Yardley DA
Am J Med Sci; 2000 Oct; 320(4):263-72. PubMed ID: 11061352
[No Abstract] [Full Text] [Related]
58. Relationship between bone mass, invasive breast cancer incidence and raloxifene therapy in postmenopausal women with low bone mass or osteoporosis.
Burshell AL; Song J; Dowsett SA; Mershon JL; Delmas PD; Secrest RJ; Cauley JA
Curr Med Res Opin; 2008 Mar; 24(3):807-13. PubMed ID: 18254988
[TBL] [Abstract][Full Text] [Related]
59. Breast cancer chemoprevention: a review of selective estrogen receptor modulators.
Johansen AM
Clin J Oncol Nurs; 2005 Jun; 9(3):317-20. PubMed ID: 15973842
[TBL] [Abstract][Full Text] [Related]
60. Bone builder vs. breast cancer.
Johns Hopkins Med Lett Health After 50; 2007 Jan; 18(11):1-2. PubMed ID: 17323491
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
